Clinical Trial

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
Protocol Amendment History 3 changes
notable Trial sites expanded: 86 -> 89 locations 2026-07-31
notable Trial sites expanded: 83 -> 86 locations 2026-05-21
notable Trial sites expanded: 78 -> 83 locations 2026-05-14
Trial Details
NCT Number NCT07089888
Lead Sponsor Crystalys Therapeutics
Conditions Tophaceous Gout
Enrollment 250 participants
Start Date 2025-08-04
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30